Latigo Biotherapeutics, Inc. Common Stock (LTGO) — Cash Flow-to-Debt Ratio
Latigo Biotherapeutics, Inc. Common Stock (LTGO) has a Cash Flow-to-Debt Ratio of -0.09x as of March 2026, meaning its operating cash flow of $-27.07 Million could theoretically repay 0% of its total liabilities ($303.16 Million) in one year. For the full cash flow conversion analysis, see Latigo Biotherapeutics, Inc. Common Stoc (LTGO) cash conversion ratio.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Latigo Biotherapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Latigo Biotherapeutics, Inc. Common Stock across 2 annual periods. See Latigo Biotherapeutics, Inc. Common Stoc (LTGO) flexibility index to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow-to-Debt Ratio for Latigo Biotherapeutics, Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Latigo Biotherapeutics, Inc. Common Stock. See Latigo Biotherapeutics, Inc. Common Stoc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.32x | $-97.56 Million | $307.19 Million | ▲ +5.0% |
| 2024 | -0.33x | $-50.95 Million | $152.46 Million | — |